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Efficacy and safety of antibiotic ‘locks’, in prevention of
thrombotic and infectious complication-related morbidity
and mortality, among diabetics dialyzed through
tunneled-cuffed catheters (TCCs) has not been effectively
investigated. This trial was designed to investigate the
outcome of TCCs (n¼ 109), inserted among 96 diabetic
end-stage renal disease patients (March 2002–February
2003), by comparing the catheter thrombosis,
catheter-related bloodstream infections (CRBSI), catheter
survival, and mortality rates, between the cohorts of 49
patients who had TCCs (n¼ 51) ‘locked’ with cefotaxime/
heparin (group I) and 47 patients with TCCs (n¼ 58) filled
with standard heparin (group II). Thrombosis was defined as
the inability to use catheter at a blood flow of 200 ml/min
despite intraluminal thrombolysis. Primary end points were
catheter thrombosis and CRBSI; elective catheter removal and
CRBSI-related death led to sensor of TCCs follow-up. Patients
with intraluminal cefotaxime/heparin lock, on cumulative
survival analysis, showed a superior thrombosis-free (86.3 vs
63.8%, P¼ 0.023, log rank), infection-free (72.9 vs 27.1%,
P¼ 0.004, log rank), and thrombosis- and infection-free TCC
survival (78.4 vs 37.9%, P¼ 0.001, log rank) at 365 days,
besides having significantly lower incidence of CRBSI (1.56 vs
3.68 episodes/1000 catheter days, Po0.0001) and CRBSI-related
mortality (9.8 vs 23.4%, P¼ 0.015), compared with the
heparin-alone group. Deployment of cefotaxime–heparin
‘lock’ enhances catheter survival; reduces thrombotic and
infectious complications and ensuing mortality, among
diabetics on dialysis. However, further studies are needed to
define the long-term implications of antibiotic locks in terms
of the risk of emergence of antimicrobial resistance.
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Diabetes mellitus has emerged as the most common cause of
end-stage renal disease (ESRD) accounting for nearly 25–40%
of patients on renal replacement therapy, worldwide.1,2 The
selection bias of surgical services and the worsening vascular
configuration among diabetic ESRD patients, who frequently
have other comorbidities, such as advanced age, obesity,
coronary artery disease, congestive heart failure, cerebrovas-
cular accidents, and/or peripheral vascular disease leading to
limb ischemia, limit their prospect of having safer permanent
vascular accesses—arteriovenous fistula and polytetrafluoro
ethylene grafts – leaving tunneled-cuffed catheters (TCCs)
with the inherent risk of thrombotic and infectious
complications, the lone long-term dialysis – access option,
for them.2,3
A close relationship exists between catheter colonization
and thrombogenesis.4,5 Catheter surface provides a nidus for
the fibrin sheath formation that facilitates bacterial adhe-
rence, colonization, and development of biofilm. Biofilms
facilitate rapid multiplication of microorganisms on the
external, as well as luminal, surfaces of the catheter, enhance
platelet aggregation, coagulation activation and also promote
thrombogenesis. This suggests that the prevention of catheter
colonization and biofilm formation through deployment of
an antimicrobial – anticoagulant lock early in the course of
catheter placement could be a plausible approach towards
achieving reductions in the incidence of catheter thrombosis,
catheter-related bloodstream infections (CRBSI) and ensuing
mortality, besides enhancing the endurance of hemodialysis
(HD) catheters.6
Antimicrobials including antibiotic – anticoagulant in-
traluminal ‘lock’ solutions using gentamicin/cephalosporins
in combination of heparin/citrate, have been reported to
improve the outcome of TCCs.7–9 However, the role of
antibiotic ‘locks’ among diabetic ESRD patients who appear
to be particularly vulnerable to thrombotic and infectious
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complications of TCCs and resultant morbidity and mortal-
ity during long-term HD, has not been exclusively
studied.10,11
RESULTS
The mean age (7s.d.) of 59.7717 (range, 31–87 years) in the
cefotaxime group (group I) was comparable to that of
57.5715 (range, 32–82 years) in the heparin-alone group
(group II). The gender ratio, proportions of the elderly and
comorbid conditions, type of TCCs (subclavian (SC)/internal
jugular catheter (IJC)), hematocrit, serum iron/ferritin,
serum albumin, glycosylated hemoglobin levels, and ade-
quacy of HD (Kt/V) were also comparable between the two
groups (Table 1).
Overall, 109 TCCs placed among 96 diabetic ESRD
patients recorded 28 episodes of catheter thrombosis
(25.7%), 107 episodes of CRBSI in 39 785 catheter days
(2.68/1000 catheter days) and this amounts to a mean
percent catheter survival at 365 days of 56.9% (62/109) and a
CRBSI-related mortality of 16.7% (16/96) during the study
period.
Patients with cefotaxime/heparin lock (group I) had
higher thrombosis-free (86.3 vs 63.8%, log rank, P¼ 0.023),
infection-free (72.9 vs 27.1%, log rank, P¼ 0.004), and
thrombosis- and infection-free TCC survival (78.4 vs 37.9%,
log rank, P¼ 0.001) at 365 days, besides having significantly
lower CRBSI rate (1.56 vs 3.68 episodes/1000 catheter days,
Po0.0001) and CRBSI-related mortality (9.8 vs 23.4%,
P¼ 0.015), compared with heparin-alone (group II). No
statistically significant survival advantage for either IJC or
SC, in any of the two groups, was observed during the study
period (Tables 2 and 3, Figures 1–3).
DISCUSSION
As catheter surface represents the real battlefield between the
bacteria and host defense mechanisms, the common objective
with the use of an antimicrobial – anticoagulant ‘lock’ had
been to create an intraluminal microenvironment intimidat-
ing to invading microorganisms and to prevent biofilm
formation that facilitates bacterial multiplication, platelet
adhesion, coagulation activation, and, consequently, thrombo-
genesis.4,12
The results from recent randomized controlled studies on
the use of antimicrobials (e.g. citrate taurolidine and 30%
trisodium citrate) and catheter-restricted filling with anti-
biotic lock solutions (aminoglycosides – gentamicin/amikacin
and cephalosporins – cefazolin/cefotaxime), in combination
of anticoagulants (heparin/citrate), are clearly supportive of a
significant role that antibiotic – anticoagulant locks could
play in reducing the incidence of catheter thrombosis and
CRBSI and these locks, thus, can enhance the infection- and/
or thrombosis-free survival rates of TCCs.13
Jurewitsch14 reported the efficacy of 2% taurolidine as a
catheter lock in the prevention of sepsis primarily in
parenteral nutrition patients with the reduction in infection
rate from 8.5 to 0.5 episodes/1000 catheter days. Later,
Sodermann15 evaluated 1.35% taurolidine and 4% sodium
citrate combination (NeutrolinTM, Biolink, Norwell, MA,
Table 1 | Clinical characteristics and demographic profile of diabetic ESRD patients in heparin-alone and cefotaxime/heparin
‘locked’ groups
Group I Group II
Patient characteristics
‘Locked’ with cefotaxime/heparin
(TCCs, n=51)
Heparin alone
(TCCs, n=58) P-value
Patients number (n=96) 49 47
Age (years7s.d., range) 59.7717 (31–87) 57.5715 (32–82) 0.887
Male (n (%)) 29 (59.2) 26 (55.3) 0.668
Female (n (%)) 20 (40.8) 21 (44.7) 0.667
Elderly (465 years) 31 (63.3) 29 (61.2) 0.885
Comorbid conditions
IHD 9 (18.4) 8 (17.0) 0.854
CHF 9 (18.4) 10 (16.9) 0.709
PVD 10 (20.4) 9 (19.1) 0.946
CVA 3 (6.4) 4 (8.2) 0.782
Hematocrit (%, mean7s.d.) 32.671.9 34.572.4 0.769
Serum iron (mg/dl, mean7s.d.) 76.478.2 79.477.6 0.735
Serum ferritin (ng/ml, mean7s.d.) 82.97179 263.47169 0.874
Serum albumin (g/dl7s.d.) 3.2970.16 3.3370.11 1.000
HbA1C (%7s.d.) 7.270.73 6.970.91 1.000
Kt/V (mean7s.d.) 1.2570.23 1.3170.19 1.000
Type of TCCs (n (%))
SC 15 (29.4) 14 (24.1) 0.623
IJC 36 (70.6) 45 (77.6) 0.636
CHF, congestive heart failure; CVA, cerebrovascular accidents; ESRD, end-stage renal disease; HbA1C, glycosylated hemoglobin; IHD, ischemic heart disease; IJC, internal
jugular catheter; PVD, peripheral vascular disease; SC, subclavian catheter; s.d., standard deviation; TCCs, tunneled-cuffed catheters.
Figures in parentheses indicate percentage.
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USA) on 71 long-term HD patients with TCCs, treated for an
average period of 16 months. Of these patients 64% had no
catheter-related infections, only 11% had CRBSI at the rate of
0.3 episodes/1000 catheter days, which was significantly lower
than in historical controls. Recently, Betjes and Van
Agteren,16 in a single-center open-label clinical trial on 76
TCCs placed among 58 patients, reported four episodes of
CRBSI in heparin group as opposed to none in patients with
catheters locked with Neutrolin (Po0.05).
Following encouraging preliminary reports by Ash et al.17
on the use of high concentration of trisodium citrate (23%
TSC), a non-antibiotic antimicrobial with local anticoagula-
tion properties) as catheter– locking solution to prevent
CRBSI, Weijmer et al.,18 in their multicenter, randomized
trial also observed enhanced overall patency (P¼ 0.005) and
reduced CRBSI rates (87%, Po0.001) for TCCs locked 30%
TSC compared with those filled with standard heparin.
However, flow problems were not reduced, and no significant
difference in the catheter-thrombosis rates between the two
groups was observed.16
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Figure 1 | Kaplan–Meier cumulative survival curves
demonstrating the probability of thrombosis-free survival
of TCCs (IJC and SC) group I (diabetic ESRD patients with
cefotaxime–heparin ‘lock’) and group II (with heparin alone)
on long-term HD.
Table 2 | Catheter events in diabetic ESRD patients in group-I (cefotaxime/heparin ‘locked) and group-II (heparin-alone)
Group I Group II
Catheter events
‘Locked’ with
cefotaxime/heparin
(TCCS, n=51)
Heparin
alone
(TCCs, n=58) RRR (%) OR 95% CI P-value
Duration of catheterization
(in catheter days)
18 615 21 170
Catheter thrombosis (n (%)) 7 (13.7) 21 (36.2) 62.2 3.455 1.639–7.368 o0.001
CRBSI episodes (n) 29 78 —
CRBSI/1000 catheter days 1.56 3.68 57.6 8.680 4.373–17.388 o0.0001
Exit site infections (n/total (%)) 9/51 (17.6) 9/58 (15.5) — 1.190 0.389–3.644 0.937
TCC survival at 365 days (n/total (%)) 40/51 (78.4) 22/58 (37.9) — 4.580 2.444–8.626 o0.0001
CRBSI-associated mortality (n/total (%)) 5/49 (9.8) 11/47 (23.4) 58.2 2.842 1.206–6.824 0.015
95% CI, 95% confidence interval; CRBSI, catheter-related bloodstream infection; ESRD, end-stage renal disease; OR, odds ratio; RRR, relative risk reduction; TCCs, tunneled-
cuffed catheters.
Figures in parentheses indicate percentage.
Table 3 | Bacterial flora isolated from the diabetic ESRD
patients with CRBSI
Episodes of CRBSI
Group I Group II
Bacterial flora isolated
‘Locked’ with
cefotaxime/heparin
(TCCs, n=51)
Heparin
alone
(TCCs, n=58)
Gram-positive bacteria
(n, total, %)
19/107 (17.8) 32/107 (29.9)
Staphylococcus epidermidis 7 13
Staphylococcus aureus 12 19
Gram-negative bacteria
(n, total, %)
10/107 (9.3) 46/107 (42.9)
Escherichia coli 3 9
Klebsiella pneumoniae 3 9
Pseudomonas aeruginosa 2 11
Acenetobactor species 1 7
Enterococcus faecalis 1 7
Serratia marcesens 0 3
Total 29/107 (27.1) 78/107 (72.8)
CRBSI, catheter-related bloodstream infection; ESRD, end-stage renal disease; TCCs,
tunneled-cuffed catheters.
Figures in parentheses indicate percentage.
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Figure 2 | Kaplan–Meier cumulative survival curves
demonstrating the probability of infection-free survival
of TCCs (IJC and SC) group I (diabetic ESRD patients with
cefotaxime–heparin ‘lock’) and group II (with heparin alone)
on long-term HD.
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Earlier Pervez et al., in a randomized controlled trial
(n¼ 33), had observed a significant decline in CRBSI (0.62 vs
2.11/1000 patient days) and catheter-thrombosis episodes
(2.5 vs 3.2/1000 patient days) besides longer mean catheter-
survival percentage at 60 days (74.0712 vs 59.0711,
P¼ 0.03) in gentamicin-citrate ‘locked’ (40 mg/ml) plus
4.6% TSC) group compared with control group having
TCCs filled with standard heparin.17 However, the study was
prematurely terminated as TSC in higher concentrations
(410%) was thought to be unsafe as TSC provides local
anticoagulation by binding to Ca2þ ; even small amounts of
citrate entering the right atrium of heart could cause life-
threatening depression of ionic Ca2þ levels in the cardiac
muscle leading to serious pacemaker dysfunction and fatal
cardiac arrhythmias. In vivo experiments suggest that the
degradation of cardiac function could occur even at lower
concentrations if TSC spills out of the catheter.15 For this
reason, Food and Drug Administration issued a warning
against the use of TSC in concentrations above 4%.18,19
Dogra et al.7 demonstrated a clear decline in the incidence
of CRBSI (0.03 vs 0.42/100 catheter days, P¼ 0.003) and
substantial increase in mean infection-free catheter survival
rate (282 vs 181 days, P¼ 0.002) in the gentamicin/TSC
(40 mg/ml and 3.13% TSC; ratio 2:1) group compared to that
of heparin group. However, predialysis gentamicin levels were
found to be significantly higher in patients randomized to
gentamicin group (2.8 mg/l vso0.2 mg/l, P¼ 0.008). Authors
cautioned to establish the safety of ‘locked’ dose of gentamicin
for ototoxicity before the adoption of the technique.7
McIntyre et al.8 recently reported symptoms compatible with
aminoglycoside ototoxicity in about 10% of patients when
TCCs had been locked with high dosages of gentamicin
(40 mg/ml) for long periods. Earlier, Saxena et al.20 in a case
report noted manifestation of sudden irreversible ototoxicity
in a diabetic ESRD patient having TCC ‘locked’ with
amikacin, to prevent recurrent episodes of CRBSI.21
Thus, the efficacy and safety of currently available
antimicrobial/antibiotic/lock protocols using sodium citrate
and/or aminoglycosides for the TCCs placed among diabetic
ESRD patients, who often have underlying cardiac and/or
hearing disability, clearly become questionable. The prefer-
ence of cefotaxime plus heparin over other antimicrobials/
anticoagulant combinations, in the present study on the
diabetic ESRD patients, was primarily based on the lack of
cardio/ototoxic potentials of the basic components of this
TCCs ‘locking’ solution.9 Even though cefotaxime was not
used earlier in catheter locks, its excellent clinical efficacy and
microbiological safety profile has been demonstrated in the
management of infections in critically ill patients.22
In the present study, the overall catheter thrombosis,
CRBSI incidence, CRBSI-related mortality, were much lower
than the published reports, whereas the percent catheter-
survival rates were comparable to those reported else-
where.2,7–11,15–18,23–25 Additionally, the diabetic ESRD patients
in cefotaxime/heparin group recorded significantly higher
thrombosis-free (log rank, P¼ 0.023), infection-free (log
rank, P¼ 0.004), and thrombosis- and infection-free TCC
survival (log rank, P¼ 0.001) at 365 days, besides having
significantly lower CRBSI rate (1.56 vs 3.68 episodes/1000
catheter days, Po0.0001) and CRBSI-related mortality (9.8
vs 23.4%, P¼ 0.015), compared with heparin-alone group.
There is no experience of any adverse reaction to the
components of lock solution.
The CRBSI episodes were mainly caused by Gram-positive
cocci – Staphylococcus aureus, S. epidermidis and Gram-
negative bacilli in both groups. Cefotaxime appeared
significantly more effective against Gram-negative bacilli
than the Gram-positive organisms. Of over all CRBSI
reduction rate of 59.5%; 78.4% reduction was observed in
the infections owing to Gram-negative bacilli against that of
40.5% in Gram-positive organisms (odds ratio¼ 5.12, 95%
confidence interval, 2.635–9.948; Po0.0001), in cefotaxime
group compared with heparin group.
No resistance to cefotaxime was observed among the
bacterial strains isolated from CRBSI episodes that occurred
during 1 year of study period. This was perhaps attributable
to the reasonably higher intraluminal concentrations of
cefotaxime and heparin in the ‘lock’ that was applied since
the time of catheter placement, permits little chance for
bacteria to enter, colonize, and form biofilm in the catheter
lumen while the ‘lock’ solution is kept locally restricted by
making even volumes of locking solution pass to the catheter
lumen to prevent the systemic spill-out of the antibiotic.
Nonetheless, there remains a concern of long-term develop-
ment of antimicrobial resistance with the use of antibiotic in
catheter locks.
Conclusion
Thus, catheter-restricted interdialytic filling of cefotaxime/
heparin seems to be a safe and effective approach towards
prevention of thrombotic and infectious complications and
related mortality with enhancement of TCC lifespan, among
diabetics on dialysis who are also vulnerable to comorbidities
related to heart and hearing. However, long-term studies
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Figure 3 | Kaplan–Meier cumulative survival curves
demonstrating the probability of thrombosis and infection-free
survival of TCCs (IJC and SC) group I (diabetic ESRD patients
with cefotaxime–heparin ‘lock’) and group II (with heparin-alone)
on long-term HD.
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would be necessary to address the issue of potential
emergence of resistant bacterial infections before antibiotic
locks could clearly become the part of standard care for
diabetics on dialysis.
MATERIALS AND METHODS
This randomized, double-blind-controlled trial was conducted at
the outpatients dialysis facility of a large tertiary care center of
Eastern Province of Saudi Arabia, to compare the efficacy of
intraluminally placed cefotaxime/heparin ‘lock’ with the regular
practice of catheter-restricted filling with standard heparin – in the
prevention of catheter thrombosis, CRBSI and ensuing mortality
among the diabetic ESRD patients. This study also endeavored to
check whether the ‘locked’ antibiotic solution had any favorable
effect on the lifespan of TCCs used so frequently in this vulnerable
group of patients on HD. Cefotaxime was selected primarily owing
to its broad spectrum, proven clinical and microbiological efficacy
and safety record, besides the lack of ototoxic potential.9,22
Patient population, selection criteria, study design, and
randomization
All the diabetic ESRD patients were eligible for the study if they
required insertion of a TCC (SC or IJC) for the maintenance or
initiation of HD between March 2002 and February 2003 at our
Tertiary Care Center. Patients who had reinsertion of a TCC through
a new access site were also included. However, subjects having active
sepsis/receiving prolonged (more than 7 days) antibiotic therapy
(oral/parenteral) or allergy to cephalosporins, were excluded from
the study. The patients who could not be randomized within three
dialysis sessions of new TCC insertion and those who had the
exchange over guidewire of a TCC through the same exit site, were
also excluded.
The randomization was performed using sequentially numbered,
opaque, sealed envelopes. The sequence of interventions was
obtained from a computer-generated random number list to ensure
the concealment of the patient’s assignment to a particular group.
All the authors/investigators, including microbiologists and HD staff
involved in the study, were blinded to the patient’s allocation to the
treatment groups. The outcomes were analyzed independent of
investigators by statisticians.
Of total identified (n¼ 126) TCC insertions among 110 diabetic
ESRD patients enrolled during study period, eventually 96 patients
with TCCs (n¼ 109) consented and were randomized to two
groups: 49 patients with TCCs (n¼ 51) to group I with
cefotaxime–heparin lock (cefotaxime, 10 mg/ml and heparin,
5000 U/ml) and 47 patients with TCCs (n¼ 58) to group II with
standard heparin lock (5000 U/ml) (Figure 4).
All the patients were dialyzed three times per week for 3–4 h
through double-lumen-cuffed Perm-caths (Quinton Instrument
Co., Seattle, Washington, DC, USA) placed by vascular surgeons
with chest radiographs taken to confirm their correct positioning.
The demographic profile, clinical characteristics, and reasons for the
TCCs insertion in the patients of each group are shown in Tables
1 and 4.
Antibiotic ‘lock’ preparation and placement
Cefotaxime sodium (Claforan, Roussel) was dissolved directly in
heparin sodium (PoM, Uniheps (Leo)) under aseptic conditions, to
obtain a final concentration of 10 mg/ml for cefotaxime and 5000 U/
ml for heparin in the ‘lock’ solution, prepared by the pharmacists,
on daily basis. Each lock volume of approximately 2.5 ml contained
25 mg of cefotaxime and 12 500 U of heparin, to fill 1.3 ml of venous
and 1.2 ml of arterial lumina of TCC, at the end of each HD session
in group I patients.26 The ‘locks’ were removed at the beginning of
each HD using sterile syringe to avoid systemic spill-out of
antibiotic during the procedure and placed again at the completion
of HD to remain in-place till next HD.
Study end points
The development of symptomatic CRBSI and/or catheter thrombo-
sis were the primary end points, whereas the events of elective
removal of the catheter and CRBSI-related death were used to sensor
the TCCs follow-up.
Thrombosis was defined as the inability to use the catheter at a
blood flow of 200 ml/min that did not respond to initial attempt of
intraluminal thrombolysis with t-plasminogen activator.
Total TCC insertions (n = 116) identified in 110 diabetic ESRD patients
101 patients with TCCs (n = 114) consented and randomized
TCCs (n = 53) in 51 patients randomized to
cefotaxime–heparin catheter-lock
TCCs (n = 61) in 50 patients randomized to
catheter-restricted filling of heparin-alone
TCCs (n = 51), in 49 patients received
cefotaxime–heparin catheter lock
(Group-1)
TCCs (n = 58), in 47 patients with
intraluminal filling of heparin-alone
(Group-II)
2 patients excluded:
One for having received
prolonged i.v. antibiotic
for peritonitis (ex-CAPD);
the other for violating
protocol
3 patients excluded:
 Two moved to the units closer
  to homes; one received
  antibiotics for extended period
  (following amputation of toes-
  diabetic foot)
Figure 4 | Study design and plan of randomization.
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Definitions and diagnosis of CRBSI
Catheter infections were diagnosed using clinical and microbio-
logical criteria as defined by the Centers for Disease Control.27
A catheter was considered colonized if growth of X15 colony-
forming units was found by semiquantitative roll-plate technique
from a proximal or distal catheter segment in the absence of clinical
signs of infection at the catheter exit site.
A catheter exit-site infection was defined as a positive (semi-)
quantitative culture of the drainage material with local signs of
inflammation.
CRBSI was considered when the same organism (i.e. identical
species, antibiogram) was isolated from a quantitative culture of the
distal segment of catheter and from the blood of a patient with
accompanying clinical signs of sepsis and no other apparent source
of infection.
Suspected cases of CRBSI were treated for 2 weeks with an
empirical regimen comprising of intravenous vancomycin and an
aminoglycoside given post-dialysis; this regimen was modified
following availability of blood culture results. Predialysis plasma
levels of aminoglycosides were monitored regularly. Catheters were
removed only if sepsis persisted (failure to render patient apyrexial
within 48 h) despite initiation of antibiotic therapy. Further, CRBSI
episodes were only categorized as new infections if they occurred no
less than two weeks after the cessation of initial successful antibiotic
therapy.28
CRBSI-related mortality was defined as death of a patient with
clinical signs of sepsis with no other obvious source of infection and
the isolation of the same organism from a quantitative blood culture
from the catheter and the peripheral blood.
Exit sites were dressed with Opsite (Smith and nephew, Hull,
UK) and kept under supervision at each HD treatment session.
Time from catheter placement to infection and/or thromboses was
estimated and expressed as period of catheterization.
Statistical analyses
The sample size of 110 TCCs (55 in each group) calculated to be of
power to detect 30% difference in the two treatments at a one-sided
0.05 level of significance, was based on the previous experience of
baseline risk of 2.5 CRBSI episodes/1000 catheter days, at this
tertiary care center.
The SPSS, version 10.1 (Chicago, IL, USA) was used for data
processing. The w2 test was used to assess the difference among the
extent of HD catheter thromboses, CRB incidence and infection-free
catheter survival between the two groups. The Student’s t-test was
used to compare between the means of two quantitative variables.
The cumulative survival curves were obtained by the Kaplan–-
Meier survival method. The prognostic significance of the catheter
thromboses and CRBSI incidence on the percent survival of TCCs in
relation to duration of catheterization was tested by cumulative
survival analysis at the main time points (the time of HD catheter
infection and/or thrombosis/removal, from the time of catheter
placement). The differences in the cumulative survival curves were
assessed by the Log-rank test.
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